Abciximab (ReoPro) Dosing Strategy for the Management of Acute Intraprocedural Thromboembolic Complications during Pipeline Flow Diversion Treatment of Intracranial Aneurysms
Conclusions: IA ReoPro administration is an effective and safe rescue strategy for the management of acute intraprocedural thromboembolic complications during PED treatment. Using a dosing strategy of either 5-mg increments or a 0.125 mg/kg IA bolus (half cardiac dosing) can provide high rates of recanalization with low rates of hemorrhagic complications and long-term morbidity.Intervent Neurol 2018;7:218 –232 (Source: Interventional Neurology)
Source: Interventional Neurology - February 27, 2018 Category: Neurology Source Type: research
In situ administration of abciximab for thrombus resolution during intracranial bypass surgery: case report.
Abstract
Abciximab is a glycoprotein IIb/IIIa receptor antagonist that functions to prevent platelet aggregation, thus reducing thrombus initiation and propagation. It has been widely used during percutaneous endovascular interventions, such as aneurysm coil embolization, angioplasty, atherectomy, and stent placement, as both a preventative and a salvage therapy. The use of abciximab in cardiac and neurosurgical procedures has been associated with a reduced incidence of ischemic complications and a decreased need for repeated intervention. In these settings, abciximab has been delivered transarterially via...
Source: Journal of Neurosurgery - January 19, 2018 Category: Neurosurgery Authors: Buchanan IA, Lee B, Amar AP, Giannotta SL Tags: J Neurosurg Source Type: research
What is the role for Glycoprotein IIb/IIIa inhibitor use in the catheterisation laboratory in the current era?
CONCLUSION: Because of the persistent benefit of GPI in limiting early ischemic complications, especially in higher risk clinical and/or anatomical subsets, and the associated risk of increased bleeding complications, also in contemporary PCI, these agents should currently be used on a selective rather than routine basis, including bail out administration for peri-procedural thrombotic complications.
PMID: 29345590 [PubMed - as supplied by publisher] (Source: Current Vascular Pharmacology)
Source: Current Vascular Pharmacology - January 16, 2018 Category: Drugs & Pharmacology Authors: Rubboli A, Patti G Tags: Curr Vasc Pharmacol Source Type: research
Abciximab/Heparin During Acute Heparin-Induced Thrombocytopenia: A Word of Caution.
PMID: 29305853 [PubMed - as supplied by publisher] (Source: The Annals of Thoracic Surgery)
Source: The Annals of Thoracic Surgery - January 3, 2018 Category: Cardiovascular & Thoracic Surgery Authors: Koster A, Morshuis M, Birschmann I Tags: Ann Thorac Surg Source Type: research
Abciximab/Heparin During Acute Heparin-Induced Thrombocytopenia: A Word of Caution
Publication date: Available online 3 January 2018 Source:The Annals of Thoracic Surgery Author(s): Andreas Koster, Michiel Morshuis, Ingvild Birschmann (Source: The Annals of Thoracic Surgery)
Source: The Annals of Thoracic Surgery - January 3, 2018 Category: Cardiovascular & Thoracic Surgery Source Type: research
Bilateral subconjunctival hemorrhage secondary to abciximab use: case report.
In this report, we present the case of a patient with bilateral subconjunctival hemorrhage after receiving abciximab.
CASE REPORT: A 40-year-old male patient underwent coronary angiography after acute anterior myocardial infarction and a coronary stent was placed. Abciximab was added to the therapy because of stent thrombosis. Bilateral subconjunctival hemorrhage was observed after the administration of the abciximab treatment. We treated our patient by stopping abciximab and administering artificial tears.
CONCLUSİON: For the first time in the literature, we presented the case of a patient with bilateral ...
Source: Sao Paulo Medical Journal - December 18, 2017 Category: General Medicine Authors: Kul S, Sayın MR Tags: Sao Paulo Med J Source Type: research
Abciximab/Heparin Therapy for Left Ventricular Assist Device Implantation in Patients With Heparin-Induced Thrombocytopenia
Conclusions This is the first report of a novel abciximab/heparin protocol for LVAD implantation in patients with HIT. The preliminary results suggest the feasibility and safety of this protocol. (Source: The Annals of Thoracic Surgery)
Source: The Annals of Thoracic Surgery - December 10, 2017 Category: Cardiovascular & Thoracic Surgery Source Type: research
Reply: Cangrelor or Abciximab as First Choice in Cardiogenic Shock
(Source: Journal of the American College of Cardiology: Cardiovascular Interventions)
Source: Journal of the American College of Cardiology: Cardiovascular Interventions - December 4, 2017 Category: Cardiology Authors: Vaduganathan, M., Qamar, A., Badreldin, H. A., Faxon, D. P., Bhatt, D. L. Tags: To the Editor Source Type: research
Cangrelor or Abciximab as First Choice in Cardiogenic Shock
(Source: Journal of the American College of Cardiology: Cardiovascular Interventions)
Source: Journal of the American College of Cardiology: Cardiovascular Interventions - December 4, 2017 Category: Cardiology Authors: Lozano, I., Rondan, J., Vegas, J. M., Segovia, E. Tags: To the Editor Source Type: research
Early angiographic signs of acute thrombus formation following cerebral aneurysm treatment with the Pipeline embolization device
Conclusions
Progressive stagnation or occlusion of covered side branches or target aneurysm are early angiographic signs of acute thrombus formation following PED placement and should prompt immediate treatment with a glycoprotein IIb/IIIa inhibitor. Platelet inhibition testing may help identify those patients who are at an increased risk for this complication. (Source: Journal of NeuroInterventional Surgery)
Source: Journal of NeuroInterventional Surgery - October 13, 2017 Category: Neurosurgery Authors: Patel, A., Miller, T. R., Shivashankar, R., Jindal, G., Gandhi, D. Tags: Neuroimaging Source Type: research
Abciximab/Heparin Therapy for Left Ventricular Assist Device Implantation in Patients With Heparin-Induced Thrombocytopenia.
CONCLUSIONS: This is the first report of a novel abciximab/heparin protocol for LVAD implantation in patients with HIT. The preliminary results suggest the feasibility and safety of this protocol.
PMID: 28987395 [PubMed - as supplied by publisher] (Source: The Annals of Thoracic Surgery)
Source: The Annals of Thoracic Surgery - October 4, 2017 Category: Cardiovascular & Thoracic Surgery Authors: Lee CL, Colombo PC, Eisenberger A, Diuguid D, Jennings DL, Han J, Salna MP, Takeda K, Kurlansky PA, Yuzefpolskaya M, Garan AR, Naka Y, Takayama H Tags: Ann Thorac Surg Source Type: research
P2Y12 hyporesponse (PRU>200) is not associated with increased thromboembolic complications in anterior circulation Pipeline
Conclusions
P2Y12 hyporesponse (PRU>200) is not associated with increased periprocedural complications in a contemporary series of patients undergoing anterior circulation PED placement. Titration of antiplatelet medications to P2Y12 >200 remains unindicated and may increase the risk of hemorrhagic complications. (Source: Journal of NeuroInterventional Surgery)
Source: Journal of NeuroInterventional Surgery - September 12, 2017 Category: Neurosurgery Authors: Bender, M. T., Lin, L.-M., Colby, G. P., Lubelski, D., Huang, J., Tamargo, R. J., Coon, A. L. Tags: Clinical neurology Source Type: research
E-022 Low dose eptifibatide for acute icad intervention results in high incidence of acute reocclusion
Conclusion
The low dose eptifibatide protocol employed here was safe in that no hemorrhages occurred. However, three of six target vessels re-occluded acutely. While the data are limited, the protocol appears to lack adequate potency to prevent re-occlusion of acutely treated ICAD lesions.
Disclosures
C. Roels: None. M. Brown: None. R. Janjua: None. D. Heck: 2; C; Stryker. (Source: Journal of NeuroInterventional Surgery)
Source: Journal of NeuroInterventional Surgery - July 23, 2017 Category: Neurosurgery Authors: Roels, C., Brown, M., Janjua, R., Heck, D. Tags: Electronic Poster Abstracts Source Type: research
E-083 Intraarterial and intravenous abciximab for management of acute in-situ thrombosis during pipeline flow diversion of intracranial aneurysms
Conclusions
IA and IV ReoPro administration is a effective and safe strategy for the management of acute in-situ thrombosis during PED, with high rates of immediate thrombosis resolution and relatively low rates of hemorrhagic complications and long term morbidity.
Disclosures:
B. Jiang: None. J. Campos: None. N. Beaty: None. E. Westbroek: None. M. Bender: None. R. Tamargo: None. J. Huang: 2; C; Longeviti. G. Colby: 1; C; Stryker. 2; C; Microvention, Medtronic. A. Coon: 2; C; Medtronic, Microvention, Sequent, Stryker. L. Lin: None. (Source: Journal of NeuroInterventional Surgery)
Source: Journal of NeuroInterventional Surgery - July 23, 2017 Category: Neurosurgery Authors: Jiang, B., Campos, J., Beaty, N., Westbroek, E., Bender, M., Tamargo, R., Huang, J., Colby, G., Coon, A., Lin, L. Tags: Electronic Poster Abstracts Source Type: research
Recombinant GPVI-Fc added to single or dual antiplatelet therapy in vitro prevents plaque-induced platelet thrombus formation.
Abstract
The efficiency of current dual antiplatelet therapy might be further improved by its combination with a glycoprotein (GP) VI-targeting strategy without increasing bleeding. GPVI-Fc, a recombinant dimeric fusion protein binding to plaque collagen and concealing binding sites for platelet GPVI, acts as a lesion-focused antiplatelet drug, and does not increase bleeding in vivo. We investigated, whether GPVI-Fc added in vitro on top of acetylsalicylic acid (ASA), the P2Y12 antagonist ticagrelor, and the fibrinogen receptor antagonist abciximab alone or in combination would increase inhibition of plate...
Source: Thrombosis and Haemostasis - June 1, 2017 Category: Hematology Authors: Mojica Muñoz AK, Jamasbi J, Degen H, Münch G, Ungerer M, Brandl R, Megens R, Weber C, Lorenz R, Siess W Tags: Thromb Haemost Source Type: research
